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A vector based on Semliki Forest virus (SFV) expressing high levels of interleukin-12 (SFV-enhIL-12) has
previously demonstrated potent antitumoral efficacy in small rodents with hepatocellular carcinoma (HCC)
induced by transplantation of tumor cells. In the present study, the infectivity and antitumoral/antiviral effects
of SFV vectors were evaluated in the clinically more relevant woodchuck model, in which primary HCC is
induced by chronic infection with woodchuck hepatitis virus (WHV). Intratumoral injection of SFV vectors
expressing luciferase or IL-12 resulted in high reporter gene activity within tumors and cytokine secretion into
serum, respectively, demonstrating that SFV vectors infect woodchuck tumor cells. For evaluating antitumoral
efficacy, woodchuck tumors were injected with increasing doses of SFV-enhIL-12, and tumor size was measured
by ultrasonography following treatment. In five (83%) of six woodchucks, a dose-dependent, partial tumor
remission was observed, with reductions in tumor volume of up to 80%, but tumor growth was restored
thereafter. Intratumoral treatment further produced transient changes in WHV viremia and antigenemia, with
>1.5-log10 reductions in serum WHV DNA in half of the woodchucks. Antitumoral and antiviral effects were
associated with T-cell responses to tumor and WHV antigens and with expression of CD4 and CD8 markers,
gamma interferon, and tumor necrosis factor alpha in peripheral blood mononuclear cells, suggesting that
immune responses against WHV and HCC had been induced. These experimental observations suggest that
intratumoral administration of SFV-enhIL-12 may represent a strategy for treatment of chronic HBV infection
and associated HCC in humans but indicate that this approach could benefit from further improvements.
Hepatocellular carcinoma (HCC) is a major public health
problem worldwide, representing the fifth most common type
of cancer. HCC is also the third leading cause of cancer-related
death, mainly because only surgical and local ablative thera-
peutic options have shown efficacy in patients with this type of
cancer (21). Approximately 80% of all HCC cases are attrib-
uted to chronic infection with hepatitis C virus and/or hepatitis
B virus (HBV). Chronic carriers of HBV have a greater than
100-fold-increased relative risk of developing HCC compared
to HBV-uninfected humans, with an annual incidence rate of 2
to 6% in cirrhotic patients. The high incidence of HCC, to-
gether with its poor prognosis and limited therapeutic options,
warrants the development of new treatment strategies for this
disease.
There is increasing evidence that stimulation of the immune
system for subsequent recognition and killing of tumor cells
may be a valuable treatment option for liver cancer. In general,
HCC appears to be an attractive target for immunotherapy
because cases of spontaneous tumor regression have been re-
ported, HCC is often infiltrated with lymphocytes, and HCC-
associated proteins such as alpha-fetoprotein may be used as
targets for immune-mediated killing of tumors (5, 49).
A promising strategy to stimulate the deficient antitumoral
immune response is based on the transfer and subsequent
expression of immunostimulatory genes in tumor cells using
viral or nonviral delivery vectors. One of the most effective
immunostimulatory cytokines is interleukin-12 (IL-12), a pro-
tein usually expressed by macrophages and dendritic cells.
IL-12 has been demonstrated to induce strong antitumoral
effects that are mediated by the stimulation of T-helper cell
type 1 (Th1) responses, including the activation of cytolytic T
lymphocytes (CTL) and natural killer cells, and by the inhibi-
tion of angiognesis (48, 50). All of these effects are dependent
on the production of gamma interferon (IFN-). Viral vectors
that are based on adenovirus have been used to deliver IL-12
into several animal models with transplantable HCC, resulting
in a localized expression of this cytokine and usually leading to
antitumoral effects (3, 14, 37). However, and despite successful
treatment of HCC in preclinical studies, a phase I clinical trial
with a first-generation adenoviral vector for delivery and ex-
pression of IL-12 in patients with primary and metastatic liver
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cancer produced only a modest antitumoral effect (41). This
poor response was probably due to the low and transient IL-12
expression in tumors. These results in humans indicated a need
for vectors with higher potency and for preclinical testing in
relevant models of HCC (i.e., large animals with spontaneous
tumors).
Vectors based on Semliki Forest virus (SFV), a member of
the alphavirus group, are highly efficient in inducing antitu-
moral responses in a variety of animal models (2, 9, 10, 39, 44,
53). The SFV vector used in the present study is based on a
viral RNA genome in which the region coding for the struc-
tural proteins has been replaced by a heterologous gene (24).
Recombinant SFV RNA can be transcribed in vitro and trans-
fected into cells, resulting in viral replication and subsequent
production of a subgenomic RNA from which the heterolo-
gous protein is expressed at very high levels. Recombinant SFV
RNA can be packaged into viral particles (vp) by cotransfect-
ing it into cells together with two helper RNAs coding for the
capsid and the envelope proteins (43). Compared to adenoviral
vectors expressing IL-12, tumor treatment with SFV vectors
expressing the same cytokine resulted in greater antitumoral
effects in a murine colon adenocarcinoma model and also in a
rat orthotopic HCC model (16, 39). The greater antitumoral
effect mediated by SFV vectors has been attributed to the
higher expression of IL-12 and to the induction of apoptosis
caused by SFV replication within tumor cells. Apoptosis leads
to the release of tumor antigens that can be taken up by
antigen-presenting cells, thereby potentiating the antitumoral
response induced by IL-12 (54). Furthermore, SFV vectors
have low immunogenicity when delivered intratumorally, al-
lowing repetitive administrations into the same tumor, which is
not possible with adenoviral vectors (38).
In the present study, the antitumoral efficacy of an SFV
vector expressing IL-12 (SFV-enhIL-12) was investigated in
woodchucks with HCC. The Eastern woodchuck (Marmota
monax) is frequently infected with the woodchuck hepatitis
virus (WHV), which is closely related to the human HBV in its
structure, genomic organization, mechanism of replication,
and course of infection (29). The woodchuck has been used as
a mammalian model for research on HBV, including the
pathogenesis of acute and chronic HBV infection, and for
preclinical evaluation of the safety and efficacy of candidate
antiviral drugs and therapeutic immunomodulators for the
treatment of chronic HBV infection (29) and prevention of
HCC (47).
All woodchucks chronically infected with WHV as neonates
develop HCC, and the median time for tumor appearance is 24
months of age (34, 47). After identification of HCC, the me-
dian survival time of woodchucks is 6 months, a situation
similar to that for patients with HCC. In addition, WHV-
induced hepatocarcinogenesis shows strong similarity to HBV-
induced carcinogenesis in humans (34, 47). These features of
HCC that are associated with persistent hepatitis virus infec-
tion make the woodchuck model unique compared to other
animal models, in which HCC is induced by a chemical car-
cinogen or by transplantation of established tumor cell lines
into immune-deficient or immune-compatible hosts. Wood-
chucks with large liver tumors that acquire malignant charac-
teristics in a stepwise process similar to HCC in humans are an
attractive and suitable model for the preclinical evaluation of
new treatment strategies for HBV-induced HCC in humans
(47).
The antitumoral efficacy of a SFV vector expressing high
levels of IL-12 (SFV-enhIL-12) was investigated in six wood-
chucks with established chronic WHV infection and primary
HCC. The results demonstrate that SFV-delivered IL-12 ex-
pression produced a dose-dependent, partial tumor remission
that was associated with a general activation of cellular im-
mune responses against HCC. The antitumoral activity, in ad-
dition to an antiviral activity against WHV, and the favorable
safety profile in woodchucks suggest that a therapeutic ap-
proach based on SFV-enhIL-12 may represent a treatment
strategy for HCC in patients with chronic HBV infection, but
the overall results also indicate that this approach needs fur-
ther improvement for inducing a complete tumor remission.
MATERIALS AND METHODS
Cell lines and animals. The BHK-21 cell line (ATCC CCL-10) was cultured in
Glasgow minimum essential medium (Invitrogen, Carlsbad, CA) supplemented
with 5% fetal bovine serum (Invitrogen) as described previously (39). The wood-
chuck HCC-derived cell line WCH17 (ATCC CRL-2082) and the human HCC-
derived cell lines HepB3 (ATCC HB-8064) and Huh7 (our laboratory stock)
were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen) supple-
mented with 10% fetal bovine serum (Invitrogen).
All experimental procedures involving woodchucks were performed under
protocols approved by the Cornell University Institutional Animal Care and Use
Committee. Woodchucks were born to WHV-negative females and reared in
environmentally controlled laboratory animal facilities at Cornell University.
Woodchucks were inoculated at 3 days of age by subcutaneous inoculation with
5  106 50% woodchuck infectious doses of a standardized WHV inoculum
(cWHV7P2) (11). Persistence of WHV infection was based on the consecutive
detection of WHV DNA and WHV surface antigen (WHsAg) in serum from 3
months of age. All chronic WHV carrier woodchucks had developed HCC at the
beginning of the study as determined by hepatic ultrasound examination and
elevated serum of -glutamyl-transferase (GGT) activity (11 IU/liter, com-
pared to 3 to 4 IU/liter in chronic WHV carrier woodchucks without HCC).
Cell transfection and virus production. Plasmids pSFV-Luc and pSFV-enh-
IL-12 and the generation of recombinant SFV vp in BHK-21 cells have been
described previously (39). Plasmid pSFV3-LacZ was kindly provided by P.
Liljestro¨m (Karolinska Institute, Stockholm, Sweden) (24). RNA synthesis from
SFV plasmids, transfection into BHK-21 cells by electroporation, and packaging
of recombinant RNA into SFV vp were performed as described previously (39,
43). Briefly, BHK-21 cells were coelectroporated with the recombinant RNA,
together with two helper RNAs (i.e., SFV-helper-C-S219A and SFV-helper-S2
RNAs), which provided in trans the capsid and the spike proteins. SFV vp were
harvested and purified by ultracentrifugation as described previously (15). Indi-
rect immunofluorescence was applied on SFV-infected BHK-21 cells to deter-
mine the titer of SFV-Luc, SFV-LacZ, and SFV-enhIL-12 recombinant virus
stocks as described previously (40). A rabbit polyclonal antiserum specific for the
nsp2 subunit of the SFV replicase was used as the primary antibody (6).
Analysis of SFV-LacZ infectivity and -galactosidase expression in vitro.
BHK-21 or HCC-derived cell lines were infected in duplicate plates with serial
dilutions of the same SFV-LacZ virus stock. Twenty-four hours later, cells from
one dish were lysed and the amount of -galactosidase protein present in the
lysate was measured as described previously (23). Cells from the duplicate dish
were stained with 5-bromo-4-chloro-3-indolyl--D-galactopyranoside (X-Gal)
(Invitrogen), and the number of cells infected with SFV-LacZ was determined.
The amount of -galactosidase protein produced per cell was calculated for each
virus dilution by dividing the amount of -galactosidase protein detected per dish
by the number of SFV-LacZ-infected cells in each dish.
Analysis of luciferase and IL-12 expression in vivo. Four woodchucks with
HCC were used to determine that the expression of luciferase and IL-12 in
hepatic tumors is dependent on the SFV dose and to verify that intratumoral
IL-12 expression mediates increases in the levels of type I and II IFNs. Animals
were anesthetized by intramuscular injection of ketamine (50 mg/kg) and xyla-
zine (5 mg/kg). A blood sample was obtained, followed by laparotomy to expose
the liver. Vector SFV-Luc or SFV-enhIL-12, each in a total volume of 0.6 ml, was
administered intratumorally into one hepatic tumor at 10 separate sites. The first
woodchuck received 1  109 vp of SFV-Luc, whereas the second woodchuck was
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administered a threefold-higher dose of SFV-Luc (i.e., 3  109 vp). The latter
woodchuck also received 3  109 vp of SFV-enhIL-12 into another hepatic
tumor. The third woodchuck was administered a fourfold-higher dose of SFV-
enhIL-12 (i.e., 1.2  1010 vp). The fourth woodchuck was left untreated, and the
hepatic tumor from this animal served as a control. Twenty-four hours later,
woodchucks were euthanized, a blood sample was obtained, and tissues (hepatic
tumors, adjacent liver tissues, and other organs) were excised and snap-frozen in
liquid nitrogen. Following homogenization in lysis buffer (phosphate-buffered
saline containing 0.05% [vol/vol] Tween20 and protease inhibitor cocktail tablets
[Complete; Roche, Basel, Switzerland]), samples were centrifuged twice for 10
min at 9,300  g. Luciferase activity in the supernatants was determined using a
conventional luminometer. IL-12 concentrations were determined in superna-
tants and in serum using a mouse p70-specific enzyme-linked immunosorbent
assay kit (BD Bioscience, Franklin Lakes, NJ). The amount of total protein
present in tissue homogenates was quantified using a standard Bradford assay.
The expression of mRNAs for IFN- and IFN- in hepatic tumor tissues was
determined by a real-time reverse transcription-PCR-based assay (see below).
Antitumoral study. Nine woodchucks of both sexes, 20 to 30 months of age,
with one or more hepatic tumors between 1.3 and 3.4 cm in diameter were used
in this study. Two weeks prior to the start of the study, hepatic tumors for
intratumoral administration of SFV-enhIL-12 or saline placebo were identified
by ultrasonography (US) and confirmed by computed tomography (CT) while
woodchucks were under general anesthesia (ketamine [50 mg/kg] and xylazine [5
mg/kg] intramuscularly). On the day of treatment (week 0), median laparotomies
were performed on anesthetized woodchucks, and grossly identifiable tumors
were located, photographed, and measured with calipers before the injection of
vector or placebo. Woodchucks then received a single dose of 3  109 vp (SFV-1
and SFV-2), 6 109 vp (SFV-3 and SFV-4), or 1.2 1010 vp (SFV-5 and SFV-6)
of SFV-enhIL-12 or the same volume (0.6 ml) of saline (control-1, control-2, and
control-3) by intratumoral injections into 10 separate sites of one tumor. Wood-
chucks were followed for 23 to 24 weeks and were euthanized thereafter. During
necropsy, the liver was exposed, and hepatic tumors were photographed and
measured.
Analysis of tumor size. The sizes of tumors treated with SFV-enhIL-12 or
placebo were determined by US and direct caliper measurements. For US, the
Aloka ProSound model SSD-3500 high-frequency ultrasound system (Walling-
ford, CT) was used. Before each imaging session, the woodchuck abdomen was
shaved to remove any hair. US imaging gel was applied to the abdomen to
improve the contact with the transducer and to obtain a clearer image. US is
strongly reflected by the ribcage, which hinders imaging of any tissue located
beneath the ribs, such as the lungs and a portion of the liver. Thus, the liver tissue
accessible for US imaging may vary between woodchucks and between imaging
sessions for the same woodchuck. In general, the left lateral, left medial, and
right medial liver lobes were routinely accessible for imaging. During imaging,
two-dimensional images were acquired in the transverse (cranial/caudal [Cr/C]),
coronal (dorsal/ventral [D/V]), and sagittal (left/right [L/R]) planes.
Tumor size was determined by US at week 0 prior to the administration of
SFV-enhIL-12 or placebo and then at 2, 4, 6, 10, 14, 18, and 23 to 24 weeks
posttreatment. Tumor diameter measurements were obtained from the digital
images captured on the hard drive of the US machine and printed on the integral
image printer at the time of the study. The transducer was moved until the image
showing the greatest tumor diameter was located. The image was frozen, and two
points on opposite sides along the circumference of the tumor were marked. The
integrated software then calculated the distance connecting the two points. Two
additional points along the circumference of the tumor which describe a diam-
eter perpendicular to the first diameter were then located and marked. The
integrated software then calculated the distance connecting these two points. In
this way, measurements of the Cr/C and D/V diameters were made. The trans-
ducer was then rotated 90 degrees and the procedure repeated. The second set
of measurements included the L/R and a repeat of the D/V diameters. For
calculating the mean tumor diameter, the two separate measurements of the D/V
diameter were averaged, followed by averaging the mean D/V diameter and the
measurements of the Cr/C and L/R diameters.
Tumor size also was determined by direct caliper measurements during lapa-
rotomy at week 0 and during necropsy at the end of the study. From woodchucks
that were euthanized because of seizures, tumor measurements were also avail-
able during subsequent necropsy. The Cr/C, D/V, and L/R diameters were
measured and averaged to calculate the mean tumor diameter. Tumor size also
was confirmed by CT prior to the start of the study, whenever possible between
6 and 10 weeks posttreatment, and at the end of the study at weeks 23 to 24.
The tumor volume was calculated based on the diameters obtained by US
using the formula V  abc/6, where a is the mean D/V diameter, b is the Cr/C
diameter, and c is the L/R diameter. This formula was chosen because most large
liver tumors (i.e., 1.5 cm in diameter) in woodchucks are irregular and closely
approximate an ellipsoid form.
Analysis of WHV serum markers. Blood samples were obtained for WHV
DNA analysis and serological testing prior to the start of the study; at week 0
prior to the administration of SFV-enhIL-12 or placebo; and then at 2, 4, 6, 10,
14, 18, and 23 to 24 weeks posttreatment. WHV DNA in serum was determined
quantitatively by dot blot hybridization (assay sensitivity, 1.0  107 WHV
genome equivalents per ml (28). WHsAg in serum was determined qualitatively
by enzyme-linked immunosorbent assay using dilutions of serum. (12) The cutoff
value of this assay was defined as 0.05 optical density unit.
Analysis of T-cell responses. For determining T-cell responses against WHV,
in vitro stimulators were used at concentrations previously determined as opti-
mal for cultures of woodchuck peripheral blood mononuclear cells (PBMCs) (31,
32). Viral antigen stimulators consisted of native 22-nm WHsAg (2 g/ml) and
synthetic peptides of WHsAg and WHcAg. WHs peptide S18 (10 g/ml; Sigma-
Genosys, The Woodlands, TX) corresponded to amino acids 341 to 360 of
WHsAg starting at the N terminus of the large surface protein (32). WHc peptide
C100-119 (10 g/ml; Sigma-Genosys) corresponded to amino acids 100 to 119 of
WHcAg starting at the N terminus of WHcAg (31). Culture medium and a
peptide unrelated to WHV (10 g/ml; Sigma-Genosys) were used as negative
controls.
Recombinant proteins that present tumor antigens in woodchuck liver were
not available for determining antitumoral T-cell responses. To circumvent this
limitation and because other studies have used soluble protein fractions of tumor
tissues for the detection of antitumoral T-cell responses, (see, e.g., references 8,
17, and 42), cell lysates of tumor (neoplastic) and normal (nonneoplastic) liver
tissues from five chronic WHV carrier woodchucks with HCC were used as
stimulators. Briefly, tissues were cut with sterile scalpels into small pieces, placed
in plastic vials, and homogenized using plastic pestles and buffer (phosphate-
buffered saline containing 0.001% [vol/vol] -mercaptoethanol [Sigma], 5% [wt/
vol] collagenase [Sigma], and 50 units/ml DNase I [Invitrogen]). Homogenates
were filtered using a 70-m filter (BD Bioscience) and centrifuged twice for 15
min at 9,300  g. Following the last centrifugation, clear supernatant from
neoplastic or nonneoplastic liver tissue samples was combined, and protein
concentrations were determined using a standard Bradford assay (Pierce, Rock-
ford, IL).
Preliminary testing of these cell lysates at concentrations ranging from 0.5 to
10.0 g total protein per ml using PBMCs from three WHV-negative wood-
chucks indicated that background proliferation following stimulation with non-
neoplastic or neoplastic liver cell lysates was low compared to that for medium
alone (e.g., the mean counts per minute following stimulation with nonneoplastic
or neoplastic liver cell lysates at a concentration of 1.0 g total protein per ml
were only 1.3- and 1.5-fold higher, respectively, than those obtained with medium
alone).
Neoplastic liver cell lysate at concentrations of 0.5, 1.0, and 2.0 g total protein
per ml then was used as a tumor antigen stimulator for testing antitumoral T-cell
responses in woodchucks following treatment with SFV-enhIL-12 or placebo.
Nonneoplastic liver cell lysate at concentrations of 0.5, 1.0, and 2.0 g total
protein per ml was used as a stimulator to control for nonspecific (negative)
T-cell responses to tumor antigens.
The in vitro proliferation assay using woodchuck PBMCs is comparable to
those performed in human studies, except that dividing cells were labeled with
[2-3H]adenine (Amersham Pharmacia Biotech, Inc., Arlington Heights, IL)
rather than [3H]thymidine because of a deficiency in woodchuck thymidine
kinase 1 transcription (26). Woodchuck PBMCs were isolated from whole blood
and stimulated as described previously (32). The cpm of triplicate PBMC cul-
tures were averaged and expressed as a stimulation index (SI) by dividing the
average sample cpm in the presence of the stimulator by that observed in the
absence of stimulator (six replicates). A SI of 3.1 was considered to represent
a positive, specific T-cell response (32).
Analysis of leukocyte surface marker and cytokine expression. The expression
of mRNAs for the woodchuck leukocyte surface markers CD3, CD4, and CD8
and the cytokines IFN-, IFN-, tumor necrosis factor alpha (TNF-), IL-6, and
IL-12 was determined in vitro by a real-time reverse transcription-PCR-based
assay (13, 30, 32). Hepatic tumor tissues were excised, snap-frozen in liquid
nitrogen, and homogenized, and total RNA was isolated using the RNeasy kit
from Qiagen (Valencia, CA). PBMCs were cultured in the presence of medium,
WHsAg (2 g/ml), tumor (neoplastic) cell lysate (1 g/ml), or normal (nonneo-
plastic) liver cell lysate (1 g/ml) and collected after 2 1/2 days. PBMCs then
were lysed and total RNA isolated using the RNeasy kit (Qiagen). Following
treatment with DNase I (Invitrogen), RNA was reverse transcribed into cDNA
with MultiScribe reverse transcriptase (Applied Biosystems, Foster City, CA)
using random hexamers. Triplicates of cDNA were amplified on an ABI Prism
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7000 sequence detection instrument (Applied Biosystems) using SYBR green
master mix (Applied Biosystems) and woodchuck-specific primers. Woodchuck
-actin mRNA expression was used to normalize target gene expression (13, 30).
Transcription levels of target genes were determined by the formula 2CT, where
CT indicates the difference in the threshold cycle between -actin and target
gene expression. Results were represented as fold change of the transcription
level in unstimulated PBMC cultures at each time point. A fold change of 3.1
was considered to represent positive, specific expression (30).
Evaluation of liver toxicity. The general health of woodchucks was evaluated
daily by observation of appearance, general behavior, and food and water intake.
Each time woodchucks were anesthetized and bled, body weight was recorded.
Complete blood counts and serum chemistry measurements were performed
prior to the start of the study, at week 0 prior to the administration of SFV-
enhIL-12 or placebo, at 6 and 14 weeks posttreatment, and at the end of the
study. Serum chemistry measurements included GGT, alkaline phosphatase,
alanine aminotransferase (ALT), aspartate aminotransferase (AST), sorbitol
dehydrogenase (SDH), total bilirubin, albumin, blood urea nitrogen, creatinine,
Na	, K	, Cl
, bicarbonate, total serum iron, iron binding capacity, and percent
iron saturation (28). Serum AST, ALT, and SDH activities are markers of
hepatocellular injury in woodchucks. Serum GGT is a marker of HCC.
RESULTS
Infection of woodchuck hepatic tumor cells with SFV vectors
results in reporter gene expression and IL-12 secretion. Al-
though SFV vectors have a broad host and cell tropism, their
infectivity in woodchucks has not been determined. The infec-
tivity of an SFV vector carrying the gene for -galactosidase
(SFV-LacZ) was first tested in vitro using the woodchuck
HCC-derived cell line WCH17. SFV infectivity and -galacto-
sidase protein expression in woodchuck cells were compared to
those in the human HCC-derived cell lines Huh7 and HepB3.
BHK-21 cells were used as a positive control because they are
infected efficiently by SFV. As shown in Table 1, the SFV-
LacZ vector was able to infect WCH17 cells, but the infection
efficiency was 22- to 35-fold lower than that in Huh7 and
HepB3 cells. In addition, -galactosidase protein expression
per cell was 3- to 10-fold lower in the woodchuck HCC-derived
cell line than in the human HCC-derived cell lines (Table 1).
In order to test if SFV vectors can infect in vivo woodchuck
hepatic tumor cells, two chronic WHV carrier woodchucks
with HCC were selected, each having three tumors with sizes
between 1 and 3 cm in diameter. The first woodchuck received
intratumorally 1  109 vp of an SFV vector expressing lucif-
erase (SFV-Luc) into one tumor (tumor 1), whereas the other
two tumors (tumors 2 and 3) were left untreated (Fig. 1A).
This woodchuck was euthanized 24 h later, and luciferase ac-
tivity in the treated and untreated tumors and in surrounding
liver tissue was measured. Luciferase activity was detected at
high levels only in the treated tumor, demonstrating that trans-
gene expression was mainly confined to the area of injection.
The second woodchuck received intratumorally 3  109 vp
of SFV-Luc into one tumor (tumor 1) and 3  109 vp of an
SFV vector expressing murine IL-12 (SFV-enhIL-12) into a
second tumor (tumor 2), whereas a third tumor was left un-
treated (Fig. 1B). Following euthanasia 24 h later, luciferase
activity and IL-12 expression in treated and untreated tumors,
adjacent liver tissues, and several other organs were measured,
as presented in Fig. 1C and D. Luciferase activity was elevated
in all sections of tumor 1 and was five- to sevenfold higher than
in the first woodchuck, which had received a threefold-lower
dose of SFV-Luc (Fig. 1A and C). Luciferase activity was low
in all other tissues analyzed, with the exception of liver tissue
surrounding tumor 1 and spleen tissue. In this woodchuck, IL-12
protein was detected at high concentrations in two sections of
tumor 2 treated with SFV-enhIL-12 (Fig. 1D). Lower IL-12 con-
centrations were also detected in other sections of tumor 2, in
proximal liver tissue, and in tumor 1 treated with SFV-Luc. The
SFV-Luc-treated tumor 1 from the first woodchuck was used as
an additional negative control, and IL-12 protein was detectable
only at background level (Fig. 1A and D). These results and the
additional observation that IL-12 was detected in serum of the
second woodchuck at a concentration of 152 ng/ml (Fig. 1E)
suggest that this cytokine was secreted from neoplastic cells of
tumor 2 following infection with SFV-enhIL-12.
For establishing a correlation between the dose of SFV-
enhIL-12 administered into a hepatic tumor and the IL-12
concentration detected thereafter in serum, a third woodchuck
received intratumorally 1.2  1010 vp of SFV-enhIL-12 into
one tumor with a size of approximately 0.7 cm in diameter (Fig.
1E). The serum IL-12 concentration determined 24 h later was
993 ng/ml. This cytokine level was approximately sevenfold higher
than that in the second woodchuck, which had received a four-
fold-lower dose of SFV-enhIL-12, suggesting that the IL-12 level
in serum is dependent on the SFV dose administered.
In order to verify that IL-12 expression from SFV-enhIL-12
induces increases in the levels of type I and II IFNs, tumor
tissue from the third woodchuck was also analyzed for the
expression of IFN- and IFN- mRNAs (Fig. 1F). Tumor
tissue from a fourth woodchuck with one untreated tumor with
a size of approximately 1.0 cm in diameter was used as a
control. Twenty-four hours after intratumoral administration
of SFV-enhIL-12, the IFN- and IFN- mRNA expression
levels in the SFV-treated tumor were 4- and 10-fold higher,
respectively, than those in the control tumor, suggesting that
the activation of any antitumoral or antiviral immune re-
sponses by SFV-enhIL-12 could be mediated via the induction
of both cytokines.
HCC treatment with SFV-enhIL-12 results in partial tumor
remission. For evaluating the antitumoral efficacy of a SFV
vector expressing murine IL-12 on established, nontrans-
planted liver tumors, pairs of woodchucks were treated intra-
tumorally with single doses of 3  109, 6  109, or 1.2  1010
vp of SFV-enhIL-12. Three other woodchucks were injected
intratumorally with saline and served as placebo-treated con-
trols. Tumor size was determined by US every 2 to 4 weeks
(Fig. 2A). Tumor size was also measured with calipers at the
day of treatment during laparotomy and again at the end of the
study during necropsy (Fig. 2B).
TABLE 1. In vitro infectivity of SFV-LacZ and -galactosidase
protein expression in woodchuck and human
HCC-derived cell lines
Cell line Cell origin Infectivity(%)a
-Galactosidase
protein expression
(pg/cell)
BHK-21 Kidney fibroblast (hamster) 100.0 55.9
WCH17 HCC (woodchuck) 0.3 1.4
Huh7 HCC (human) 6.7 14.4
HepB3 HCC (human) 10.6 5.0
a SFV infectivity in HCC-derived cell lines is presented as a percentage of the
SFV infectivity in BHK-21 cells, which was set at 100%.
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A dose-dependent, transient reduction in tumor size was
observed by US in all woodchucks treated with SFV-enhIL-12.
Reductions started immediately following treatment, were
maximal between 2 and 4 weeks posttreatment, and lasted for
another 2 to 8 weeks thereafter. Tumor remission in SFV-
treated woodchucks, however, was only partial, and tumor
growth was restored between 6 and 14 weeks posttreatment.
One of two woodchucks (SFV-3) treated with the intermediate
dose of SFV-enhIL-12 was euthanized at 3 weeks posttreat-
ment due to seizures, but this animal also demonstrated a
remarkable reduction in tumor size (Fig. 2B). On average,
treatment with SFV resulted in a reduction of tumor volume of
58% at 4 weeks posttreatment (Fig. 2C), with four of six ani-
mals demonstrating reductions of 70%. The difference in
mean tumor volume between SFV-treated and control wood-
chucks was statistically significant at 4 weeks posttreatment
(P  0.05; two-tailed Student’s t test).
Partial tumor remission is associated with activation of
antitumoral immune responses. Cellular immune responses
elicited in woodchucks following treatment of HCC with SFV-
enhIL-12 were determined in vitro by proliferation of T cells
and expression of leukocyte surface markers and Th1 cytokines
in PBMC cultures in response to stimulation with tumor anti-
gens. Recombinant proteins that present tumor antigens in
woodchuck liver were not available; therefore, a combined cell
lysate of neoplastic liver tissues from five chronic WHV carrier
woodchucks with HCC was used for cell stimulation.
Prior to treatment with SFV-enhIL-12, T-cell responses to
tumor antigens were essentially undetectable in chronic WHV
carrier woodchucks with HCC, because SIs were below the
assay cutoff value of 3.1 (Fig. 3A). Following treatment with
SFV-enhIL-12, all woodchucks had increases in their T-cell
response to tumor antigens, and in two, T-cell response be-
came positive, with SIs of 3.1. The T-cell response was tran-
FIG. 1. Infectivity of SFV vectors in chronic WHV carrier woodchucks with HCC. (A) One woodchuck received intratumorally 1  109 vp of
SFV-Luc into one tumor with a size of approximately 3 cm in diameter (tumor 1). Two other tumors with sizes between approximately 1 and 3
cm in diameter were left untreated (tumors 2 and 3). Luciferase activity in tumor and liver homogenates was determined 24 h later. (B) A second
woodchuck received intratumorally 3  109 vp of SFV-Luc into one tumor (tumor 1 [T1]) and 3  109 vp of SFV-enhIL-12 into another tumor
(T2). The picture shows the liver at necropsy, and SFV-treated tumors (T1 and T2) are indicated by dotted circles. Both tumors had sizes of
approximately 2 cm in diameter. A third tumor (tumor 3) with a size of 3 cm was left untreated (not visible in the picture). (C and D) Luciferase
activity (C) and IL-12 protein concentrations (D) in homogenates of tumors, liver, and organs from the second woodchuck were determined 24 h
later as indicated. Tumors 1 and 2 were divided into five sections (a to e), and each section was analyzed separately for luciferase activity and IL-12
protein concentration. SFV-Luc-treated tumor 1 from the first woodchuck (A) was used as an additional negative control for the analysis of
intratumoral IL-12 expression (D). (E) The IL-12 protein concentrations in serum in the second woodchuck and in a third woodchuck that received
1.2 1010 vp of SFV-enhIL-12 into one tumor with a size of approximately 0.7 cm in diameter were determined 24 h later. (F) Tumor homogenates
from the third woodchuck and from an untreated control woodchuck with one tumor with a size of approximately 1 cm in diameter were analyzed
24 h later for the expression of IFN- and IFN- mRNAs. Pre, pretreatment; post, posttreatment.
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sient, peaked around the time of maximum tumor remission,
and declined thereafter (Fig. 2 and 3). In contrast, none of the
control woodchucks had comparable changes in the tumor
antigen-specific T-cell response. Liver antigens (i.e., a com-
bined cell lysate of nonneoplastic liver tissues from the same
woodchucks described above) were used as a control stimula-
tor, and T-cell responses against these antigens were not de-
tected in any woodchuck, demonstrating the specificity of the
antitumoral T-cell response following treatment with SFV-
enhIL-12 (Fig. 3B).
The results for antitumoral T-cell responses were extended
by determining the mRNA expression of leukocyte surface
markers and cytokines in PBMC cultures stimulated with tu-
mor antigens (Table 2). Compared to the pretreatment expres-
sion, treatment with SFV-enhIL-12 resulted in increased
expression (2.1-fold above the mRNA expression in unstimu-
lated PBMC cultures but below the assay cutoff value of 3.1)
or positive expression (3.1) of CD3, CD4, and CD8 in all
woodchucks analyzed at 6 weeks posttreatment. At this time
point the expression of IFN- was positive in tumor antigen-
stimulated PBMC cultures from all SFV-treated woodchucks
analyzed. Elevated IFN- expression correlated with increases
in the expression of TNF-, IL-6, and woodchuck IL-12, and
expression of these cytokines was positive in both woodchucks
treated with the highest dose of SFV-enhIL-12. Expression of
leukocyte surface markers and cytokines was transient, peaked
around the time of maximum tumor remission, and declined
thereafter (Fig. 2 and Table 2). Comparable changes in leuko-
cyte surface marker and cytokine expression were not observed
in tumor antigen-stimulated PBMC cultures from control
woodchucks and in liver antigen-stimulated PBMC cultures
from all woodchucks (Table 2), demonstrating again the spe-
cific activation of antitumoral immune responses following
treatment with SFV-enhIL-12.
Intratumoral SFV treatment results in antiviral effects and
antiviral immune responses. Following treatment of HCC with
SFV-enhIL-12, all woodchucks demonstrated a transient re-
duction in serum WHV DNA concentrations ranging between
0.4 and 2.5 logs10 units from pretreatment concentrations (Fig.
4A). Reductions in WHV DNA were associated with a 1.2- to
1.7-fold decline in serum WHsAg from pretreatment levels in
most woodchucks (Fig. 4B), although the transient changes in
WHs antigenemia were less pronounced than those in WHV
viremia. Decreases in WHV DNA occurred immediately fol-
FIG. 2. Tumor sizes in chronic WHV carrier woodchucks following intratumoral treatment with increasing doses of SFV-enhIL-12. Pairs of
woodchucks received intratumorally single doses of 3  109 vp (SFV-1 and SFV-2), 6  109 vp (SFV-3 and SFV-4), or 1.2  1010 vp (SFV-5 and
SFV-6) of SFV-enhIL-12 into one hepatic tumor of between 1.3 and 3.4 cm in diameter. Control woodchucks received intratumorally a single dose
of saline as placebo into one hepatic tumor of between 1.3 and 3.2 cm in diameter (Control-1, Control-2, and Control-3). (A and B) Tumor sizes
were determined by US every 2 to 4 weeks (A) and by direct caliper measurements at the day of treatment during laparotomy and at the end of
the study during necropsy (B). Woodchuck SFV-3 was euthanized 3 weeks after treatment because of seizures. (C) Mean changes in tumor volumes
in SFV- and saline-treated woodchucks based on US measurements between weeks 0 and 10. Changes are expressed as a percentage of the tumor
volume at pretreatment, which was set at 100%. Mean percentages and standard deviations are displayed. The asterisk indicates that the mean
tumor volume in woodchucks treated with SFV-enhIL-12 was statistically different from that in placebo-treated control woodchucks at 4 weeks
posttreatment (P  0.05; two-tailed Student’s t test).
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lowing treatment and were maximal between 2 and 10 weeks
posttreatment. This was followed by recrudescence of viral
replication in all woodchucks. Declines in serum WHsAg fol-
lowed a kinetic similar to that of WHV DNA, with maximum
reductions between 2 and 6 weeks posttreatment. Comparable
changes in WHV markers were not observed in sera of control
woodchucks.
The antiviral effects induced by treatment with SFV-enh-
IL-12 were associated with the development of cellular im-
mune responses to WHV (Fig. 5A to C). Prior to treatment
with SFV-enhIL-12, T-cell responses to WHV peptides were
undetectable in woodchucks, with SIs below 3.1. Following
treatment, SFV-treated woodchucks had increases in their
WHV-specific T-cell responses, and three of them developed a
positive T-cell response to WHc peptide C100-110, with SIs of
3.1. One woodchuck treated with the highest SFV dose
(SFV-5) also had a positive T-cell response to WHs peptide
S18. WHV-specific T-cell responses were transient, peaked
around the time of maximum reduction in WHV viremia and
WHs antigenemia, and declined thereafter. Control wood-
chucks had no comparable changes in their WHV-specific T-
cell responses, and T-cell responses to a control peptide
unrelated to WHV were not detected in any woodchuck.
Furthermore, all SFV-treated woodchucks had increased (SI
of 2.1) or positive (SI of 3.1) expression of CD3, CD4, and
CD8 in PBMC cultures stimulated with WHsAg (Table 3).
IFN- expression was positive in PBMC cultures from most
SFV-treated woodchucks and correlated with increases in the
expression of TNF-, IL-6, and IL-12. Leukocyte surface
marker and cytokine expression was transient, with a peak
around the time of maximum reduction in serum WHV mark-
ers. Comparable changes in expression were not observed in
WHsAg-stimulated PBMC cultures from control woodchucks,
demonstrating the specific activation of antiviral immune re-
sponses by SFV-enhIL-12.
Intratumoral SFV treatment induces no systemic toxicity.
No clinical signs of toxicity were observed in woodchucks follow-
ing treatment of HCC with SFV-enhIL-12 (Fig. 6A to C).
Changes in body weights of woodchucks treated with low and
intermediate doses of SFV-enhIL-12 were similar to those in
control woodchucks, except in woodchuck SFV-3, which was eu-
thanized at 3 weeks posttreatment due to seizures. A subsequent
necropsy of this woodchuck revealed end-stage HCC but also
indicated signs of brain damage, both of which could be the cause
for the seizures. Encephalopathy in this woodchuck induced by
SFV-enhIL-12 was excluded, as immunohistochemical staining
for the nsp2 subunit of the SFV replicase demonstrated the ab-
sence of replicating SFV in brain tissue (data not shown). On the
other hand, encephalopathy is frequently found in patients with
acute and chronic liver disease (18), and although there are no
data available for woodchucks with chronic hepatitis, it is possible
that a certain percentage of woodchucks with chronic liver disease
may develop hepatic encephalopathy. Following administration
of the highest SFV dose, a modest loss in body weight was ob-
served at 2 weeks posttreatment, but changes were transient and
both woodchucks gained weight thereafter. The hematological
and biochemical profiles of SFV-treated woodchucks were similar
to those of control woodchucks following treatment, except for
blood Na	 and Cl
 levels, which were transiently reduced in most
SFV-treated woodchucks at 6 weeks posttreatment (data not
shown). Most SFV-treated woodchucks had moderate increases
in serum SDH activity at 6 weeks posttreatment (and later), but
changes were transient. Increases in SDH activity during this time
were almost always associated with proportional elevations in
ALT and AST activities (data not shown), suggesting increased
hepatic injury. Serum activity of GGT, a marker of HCC devel-
FIG. 3. Antitumoral T-cell responses of chronic WHV carrier woodchucks following intratumoral treatment with increasing doses of SFV-
enhIL-12. (A) T-cell responses to tumor antigens (i.e., clear supernatant of a combined cell lysate of neoplastic liver tissues from five chronic WHV
carrier woodchucks with HCC at a concentration of 1.0 g/ml). (B) T-cell responses to liver antigens (i.e., clear supernatant of a combined cell
lysate of nonneoplastic liver tissues from the same woodchucks described above at a concentration of 1.0 g/ml). The T-cell response was
considered positive if the SI was 3.1, as indicated by the dotted line.
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opment in woodchucks, continuously increased in most wood-
chucks following treatment, except in woodchucks treated with
the highest SFV dose, with a transient reduction at 4 weeks
posttreatment. At the end of the study, serum GGT activity
reached the highest level in all SFV- and saline-treated wood-
chucks.
DISCUSSION
In previous studies it was shown that SFV-enhIL-12 induced
sustained antitumoral responses in several transplantable liver
tumor models, including a rat orthotopic HCC model (16, 39).
Although these results suggested that SFV vectors could have
potential application for the treatment of HCC, the efficacy
and safety of SFV-enhIL-12 need to be evaluated in more
relevant models of HCC before being applied to humans. The
woodchuck model of HBV infection and associated liver dis-
eases was chosen because all woodchucks chronically infected
with WHV ultimately develop HCC, which is comparable to
HBV-induced hepatocarcinogenesis in humans (34, 47). Addi-
tional advantages of the woodchuck model are the outbred
nature of the animals; the heterogeneity of liver tumors, re-
sembling the situation in humans; and that tumors of relatively
large size can be subjected to anticancer treatment.
Although SFV vectors have a broad tropism, their infectivity
in woodchuck hepatic tumor cells was unknown. An initial
study demonstrated that the in vitro infectivity of SFV-LacZ in
the woodchuck HCC-derived cell line WCH17 was about 300-
fold lower than that observed in BHK-21 cells, which are the
standard cells for testing SFV infectivity (Table 1). Further-
more, SFV infectivity and -galactosidase protein expression in
WCH17 cells were much lower than in the human HCC-derived
cell lines HepB3 and Huh7 (Table 1), suggesting that SFV vectors
could be efficient for gene delivery to human HCC.
TABLE 2. Tumor and liver antigen-specific expression of leukocyte surface markers and cytokines in woodchucks following intratumoral
administration of SFV-enhIL-12 at increasing doses
Antigen Woodchuck SFV dose (vp) Wk
Fold change in mRNA expression in antigen-stimulated PBMC culturesa
CD3 CD4 CD8 IFN- TNF- IL-6 IL-12
Tumor SFV-2 3  109 0 1.2 1.1 1.2 1.4 1.3 1.5 1.3
6 3.0 2.2 3.1 10.7 4.1 2.4 3.4
14 2.1 1.7 2.0 4.5 2.2 2.6 2.3
SFV-4 6  109 0 1.4 1.4 1.7 1.6 1.4 1.4 1.5
6 2.6 2.1 2.7 3.7 2.8 2.9 2.7
15 1.8 1.8 1.4 2.0 1.7 1.7 1.8
SFV-5 1.2  1010 0 1.7 1.2 1.5 1.4 1.2 1.1 1.4
6 6.3 6.9 5.2 9.0 4.4 3.9 4.0
14 1.6 1.1 1.2 1.4 1.3 1.3 1.6
SFV-6 1.2  1010 0 1.2 1.4 1.2 1.1 1.0 ND ND
6 3.7 3.3 3.8 4.1 3.2 4.0 4.5
14 1.7 1.8 2.0 1.6 2.0 1.8 2.2
22 1.5 1.5 1.5 1.1 1.7 1.3 1.4
Control-2 0 0 0.9 1.0 1.0 ND 1.2 1.0 1.4
6 1.0 1.2 1.0 1.1 1.0 1.8 1.1
14 1.8 1.7 1.3 2.4 1.6 1.6 1.6
Control-3 0 0 1.3 1.3 1.1 1.5 1.2 1.2 1.3
6 1.3 1.2 1.3 1.3 1.3 1.5 1.3
15 1.3 1.3 1.3 1.6 1.2 1.6 1.4
Liver SFV-2 3  109 0 1.2 1.3 1.1 1.5 1.0 1.1 1.3
6 1.8 1.6 1.6 2.4 1.9 1.6 1.8
14 1.2 1.1 1.1 1.9 1.4 1.5 1.4
SFV-4 6  109 0 1.2 1.1 1.3 1.3 1.1 1.4 1.4
6 1.6 1.5 1.8 1.9 1.7 1.6 1.9
15 1.6 1.4 1.3 1.4 1.5 1.5 1.6
SFV-5 1.2  1010 0 1.2 1.5 1.1 1.0 1.1 1.0 1.1
6 1.4 1.4 1.1 1.7 1.5 1.2 1.6
14 1.2 1.0 1.1 1.1 1.2 1.2 1.2
SFV-6 1.2  1010 0 1.3 1.1 1.1 1.0 1.1 1.2 1.1
6 1.4 1.3 1.1 1.5 1.4 1.2 1.1
14 1.2 1.3 1.4 1.6 1.1 1.2 1.4
22 1.0 1.1 1.2 0.9 1.0 1.3 ND
Control-2 0 0 0.9 1.0 1.0 ND 1.3 1.0 1.1
6 1.6 1.3 1.3 1.5 1.5 1.6 1.7
14 1.5 1.1 1.2 1.6 1.4 1.6 1.6
Control-3 0 0 1.4 1.2 1.1 1.3 1.2 1.4 1.2
6 1.2 1.3 1.3 1.6 1.5 1.3 1.1
15 1.6 1.3 1.5 ND 1.5 1.8 ND
a The mRNA expression of leukocyte surface markers (i.e., CD3, CD4, and CD8) and cytokines (IFN-, TNF-, IL-6, and IL-12) in PBMC cultures stimulated with
tumor antigens, or with liver antigens as a control stimulator, was compared to that in unstimulated PBMC cultures from the same woodchuck at each time point. Values
in bold were above the assay cutoff of3.1 and were considered positive for antigen-specific mRNA expression. Underlined values were below the assay cutoff but were
2.1-fold above the mRNA expression in unstimulated PBMC cultures. ND, undetectable.
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Despite the rather low infectivity and reporter gene expression
in vitro, the intratumoral inoculation of SFV-Luc into two wood-
chucks resulted in relatively high luciferase activity in vivo, which
was dose dependent and mainly confined to the infected tumor, in
addition to the secretion of IL-12 at high levels expressed from
SFV-enhIL-12 that was administered in parallel (Fig. 1). How-
ever, luciferase activity was about 10- to 100-fold lower than that
observed in mouse tumors inoculated with an equivalent dose of
SFV-Luc (38), suggesting that SFV vectors have only moderate
infectivity in woodchuck tumor cells.
FIG. 4. Antiviral effects in chronic WHV carrier woodchucks following intratumoral treatment with increasing doses of SFV-enhIL-12.
(A) Changes in serum WHV DNA concentrations. (B) Changes in serum WHsAg levels. ge, WHV genomic equivalents (virion- or WHV
DNA-containing virus particles).
FIG. 5. Antiviral T-cell responses of chronic WHV carrier woodchucks following intratumoral treatment with increasing doses of SFV-enhIL-
12. (A) T-cell responses to a synthetic peptide of the WHV core protein (WHc peptide C100-119; 10 g/ml). (B) T-cell responses to a synthetic
peptide of WHsAg (WHs peptide S18; 10 g/ml). (C) T-cell responses to a synthetic control peptide unrelated to WHV (10 g/ml). The T-cell
response was considered positive if the SI was 3.1, as indicated by the dotted line.
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Despite the low infectivity in woodchuck HCC, SFV-enhIL-12
induced a dose-dependent antitumoral effect in wood-
chucks. The effect on tumor growth was most pronounced
following treatment with the highest dose of SFV-enhIL-12,
resulting in tumor volume reductions of 71% and 80% in
woodchucks SFV-5 and SFV-6, respectively (Fig. 2). Partial
tumor remission was transient, and tumors started to grow
again between 6 and 14 weeks posttreatment. As a conse-
TABLE 3. WHV antigen-specific expression of leukocyte surface markers and cytokines in woodchucks following intratumoral administration
of SFV-enhIL-12 at increasing doses
Woodchuck SFV dose (vp) Wk
Fold change in mRNA expression in WHsAg-stimulated PBMC culturesa
CD3 CD4 CD8 IFN- TNF- IL-6 IL-12
SFV-2 3  109 0 1.4 1.2 1.2 ND 1.4 1.3 ND
6 4.5 3.3 2.7 7.4 3.4 3.1 4.7
14 2.7 2.4 2.2 3.1 2.4 2.1 2.5
SFV-4 6  109 0 1.2 1.4 1.1 1.3 1.2 1.0 1.2
6 2.4 2.4 2.3 2.9 2.7 2.7 2.9
15 2.2 1.8 2.0 2.2 1.8 1.9 1.9
SFV-5 1.2  1010 0 1.4 1.3 1.4 1.1 1.2 1.1 1.3
6 5.4 5.6 4.0 12.3 4.5 3.3 3.9
14 2.2 2.2 2.3 2.3 2.0 2.2 2.4
SFV-6 1.2  1010 0 1.1 1.1 1.0 1.2 1.1 1.0 1.1
6 2.4 2.5 2.6 3.5 2.5 2.8 2.6
14 1.5 1.2 1.4 1.6 1.7 1.1 1.4
22 1.2 1.3 1.4 1.3 1.6 1.5 1.3
Control-2 0 0 1.6 1.4 1.3 ND 1.2 1.1 1.4
6 1.4 1.2 1.1 1.1 1.6 1.6 1.4
14 1.4 1.3 1.2 1.2 1.7 1.2 1.7
Control-3 0 0 1.1 1.2 1.0 1.1 1.1 1.1 1.1
6 1.4 1.3 1.2 1.5 1.5 1.3 1.3
15 1.1 1.0 1.2 1.2 1.2 1.4 1.1
a The mRNA expression of leukocyte surface markers (i.e., CD3, CD4, and CD8) and cytokines (IFN-, TNF-, IL-6, and woodchuck IL-12) in PBMC cultures
stimulated with WHsAg was compared to that in unstimulated PBMC cultures from the same woodchuck at each time point. Values in bold were above the assay cutoff
of 3.1 and were considered positive for WHsAg-specific mRNA expression. Underlined values were below the assay cutoff but were 2.1-fold above the mRNA
expression in unstimulated PBMC cultures. ND, undetectable.
FIG. 6. Body weight and liver enzymes of chronic WHV carrier woodchucks following intratumoral treatment with increasing doses of
SFV-enhIL-12. (A) Changes in body weight. (B) Changes in serum SDH activity. (C) Changes in serum GGT activity. IU, international units.
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quence of this regrowth, most SFV-treated tumors reached a
size at the end of the study that was comparable in some cases
to the tumor sizes observed in control woodchucks. Direct
caliper measurement of tumor size during the transient anti-
tumoral response was possible in only one of the woodchucks
treated with the intermediate dose of SFV-enhIL-12, which
was euthanized because of seizures. In this woodchuck (SFV-
3), a 66% reduction in tumor volume was observed within 3
weeks, demonstrating the efficacy of the applied treatment.
Overall, the tumor sizes determined by direct caliper measure-
ment at laparatomy or necropsy (and by CT measurement
[data not shown]) correlated with those determined by US at
the same time points, suggesting that US measurements are a
simple and reliable method to evaluate tumor growth in wood-
chucks.
Two studies so far have tested viral vectors for treatment of
HCC using woodchucks. Both studies were based on intratu-
moral injection of a first-generation adenoviral vector for the
expression of murine IL-12 and the coestimulatory factor B7.1
(35) or herpes simplex virus thymidine kinase (4). Intratumoral
expression of IL-12 and B7.1 resulted in an average tumor size
reduction of 80%, which was observed in four woodchucks
between 1 and 2 weeks posttreatment (35), an antitumoral
efficacy comparable to that observed in woodchucks treated
with the highest dose of SFV-enhIL-12 in our study. In the
previous study (35) tumor reduction was maintained for 7
weeks in one woodchuck, but the other woodchucks were eu-
thanized shortly after maximum tumor remission, making it
difficult to estimate the sustainability of the induced antitu-
moral effect. In contrast, treatment with herpes simplex virus
thymidine kinase followed by administration of ganciclovir did
not induce tumor regression, although necrotic areas were
present in tumors at 1 week posttreatment (4).
Partial tumor remission following treatment with SFV-
enhIL-12 was associated with the induction of an antitumoral
immune response, as demonstrated by T-cell proliferation and
expression of leukocyte surface markers and cytokines in re-
sponse to tumor antigens (Fig. 3 and Table 2). Antitumoral
immune responses peaked at week 6 posttreatment, around
the time of maximal tumor remission, suggesting that tumor
antigens were released, most probably by SFV-induced apop-
tosis. The apoptotic bodies generated following SFV infection
could be subjected to cross-priming by host dendritic cells that
would capture, process, and present tumor-associated cellular
antigens to naive T cells, thereby inducing tumor antigen-
specific CTL responses (1). The increased expression of CD8
in tumor antigen-stimulated PBMC cultures of SFV-treated
woodchucks suggests that tumor-specific CTL responses were
induced. Increased CD8 marker expression was also observed
in woodchucks following HCC treatment with an adenovirus
expressing IL-12/B7.1 (35).
Although the induction of apoptosis in liver tumor cells by
replicating SFV itself could be partially responsible for the
antitumoral immune responses observed in woodchucks, due
to the limited number of animals that were available and suit-
able for the present study, it was not possible to control for this
effect by treating additional woodchucks with an SFV vector
expressing a reporter gene. However, studies with a mouse
model have shown that the antitumoral effects mediated by
SFV are dependent on the (high) expression of IL-12 (39),
because treatment of subcutaneous tumors with SFV-LacZ in
mice following transplantation of MC38 cells induced tumor
regression in only 9% of animals. Tumor regression increased
significantly to 92% when mice were treated with the same
dose of SFV-enhIL-12, demonstrating that an SFV vector ex-
pressing a reporter gene has very limited antitumoral efficacy.
In addition to the antitumoral effect, HCC treatment with
SFV-enhIL-12 also resulted in a transient reduction of WHV
viremia in all woodchucks that was associated in some cases
with a transient decline in WHs antigenemia (Fig. 4). Although
changes in WHV DNA were variable among individual wood-
chucks, a greater-than-30-fold reduction was observed in half
of the woodchucks. Maximum reduction in WHV viremia was
observed between 2 and 10 weeks posttreatment, followed by
viral recrudescence in all woodchucks. Sustained antiviral ef-
fects have been observed previously in woodchucks without
HCC following long-term treatment with an adenoviral vector
expressing IL-12 (13). Because WHV replication appears to be
minimal or undetectable in woodchuck HCC compared to
normal liver tissue using in situ hybridization and immunohis-
tochemistry for the detection of WHV DNA and proteins (22,
27, 36, 47, 51), SFV-mediated apoptosis of tumor cells seems
less likely to be responsible for the transient reduction in WHV
viremia. However, the antiviral effect was associated with the
induction of an antiviral immune response as demonstrated by
T-cell responses to WHV antigens and by expression of leu-
kocyte surface markers and cytokines in WHsAg-stimulated
PBMC cultures (Fig. 5 and Table 3). This suggests that CTL-
mediated killing of WHV-infected hepatocytes and/or cyto-
kine-mediated downregulation of WHV replication in liver
cells was most likely responsible for the transient reduction in
WHV viremia as indicated by increased expression of CD8 and
IFN- in PBMC cultures. It was not possible to study directly
the induction of type I and II IFNs in tumors of SFV-enhIL-
12-treated woodchucks following expression of IL-12 because
such tissues were not available until the end of the study (i.e.,
up to 6 months following treatment). For investigating a pos-
sible role of type I and II IFNs, an additional woodchuck
received intratumorally the highest dose of SFV-enhIL-12, and
the expression of IFN- and IFN- mRNAs in hepatic tumor
tissues was determined 24 h later (Fig. 1F). Because IFN- and
IFN- levels were increased in the SFV-treated tumor com-
pared to an untreated control tumor, this result suggests that
the antiviral (and antitumoral) responses observed in the SFV-
treated woodchucks could be mediated by the induction of
type I and II cytokines.
The parallel induction of antitumoral and antiviral immune
responses was also observed in HBV-infected patients with
HCC following intratumoral treatment with an oncolytic pox-
virus expressing granulocyte-monocyte colony-stimulating fac-
tor (25). The antitumoral and antiviral effects observed in this
study were attributed to the expression of granulocyte-mono-
cyte colony-stimulating factor and to virus-mediated killing of
tumor cells that resulted in the release of tumor and viral
antigens and uptake by antigen-presenting cells. The latter
effects are also mediated by SFV vectors, which are not
oncolytic but can replicate and induce apoptosis in tumor
cells (33, 54).
Treatment of HCC in woodchucks with SFV-enhIL-12 dem-
onstrated a favorable safety profile with moderate increases in
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the serum activity of liver enzymes and a modest, transient
reduction in body weight following administration of the high-
est SFV dose (Fig. 6). However, no survival benefit was ob-
served in SFV-treated woodchucks, which was most likely due
to the tumor regrowth following partial tumor remission and to
the appearance of several new tumor nodules during the end
stage of HCC (data not shown).
The observation that transient rather than sustained antitu-
moral and antiviral effects were achieved in woodchucks fol-
lowing intratumoral administration of a single dose of SFV-
enhIL-12 indicates that this approach to HCC treatment could
benefit from further improvements. Both effects may likely be
sustained in a future woodchuck study by administering a dose
of SFV-enhIL-12 exceeding 1.2  1010 vp, which was the high-
est dose used in the present study; by using a SFV vector that
expresses woodchuck IL-12 instead of mouse IL-12; and by
administering multiple vector doses over time into one or sep-
arate hepatic tumors, all of which could be performed by US-
guided intratumoral injections, thereby eliminating the need
for exposing the liver during laparotomy. The kinetics of par-
tial tumor remission and regrowth in woodchucks also suggest
that the timing for additional vector injections might be critical
and that SFV-enhIL-12 should be readministered when maxi-
mal reductions in tumor growth following initial treatment are
observed (i.e., before tumor growth is restored). In addition,
administration of a combination of vectors for the expression
of IL-12 and other cytokines such as IL-15 and IL-18 could be
considered for the treatment of HCC. Because long-term
treatment with an adenoviral vector expressing IL-12 resulted
in sustained antiviral effects in chronic WHV carrier wood-
chucks (13), repeated intratumoral administration of SFV-
enhIL-12 for the short-term expression of IL-12 in combination
with peritumoral administration of the adenoviral vector for
the long-term expression of IL-12 could be tested as a treat-
ment strategy for HCC in woodchucks. The antitumoral effi-
cacy of IL-15 and IL-18 has been demonstrated in several
animal models of cancer (7, 19, 20, 45, 46, 52), and a combi-
nation of SFV and adenoviral vectors expressing IL-12, IL-15,
or IL-18 could be also tested in the woodchuck model for
inducing sustained antitumoral effects.
In summary, the present study demonstrates that the anti-
tumoral efficacy mediated by an SFV vector expressing IL-12 is
not limited to transplantable models in small rodents and
therefore may represent a strategy for the treatment of chronic
HBV infection and associated HCC and, by analogy, of other
types of HCCs in humans.
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